Related Experiment Video
Updated: Feb 22, 2026

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia
Published on: December 22, 2023
Arrhythmogenic Cardiomyopathy
Domenico Corrado1, Cristina Basso2, Daniel P Judge2
1From the Department of Cardiac, Thoracic, and Vascular Sciences, University of Padova Medical School, Italy (D.C., C.B.); and Department of Medicine/Cardiology, Center for Inherited Heart Disease, Johns Hopkins University School of Medicine, Baltimore, MD (D.P.J.). domenico.corrado@unipd.it.
Insights
Arrhythmogenic cardiomyopathy is an inherited heart muscle disorder causing sudden cardiac death, especially in young individuals. Diagnosis uses a scoring system, and preventing sudden cardiac death via implantable cardioverter defibrillators is key, despite associated risks.
Area of Science:
- Cardiology
- Genetics
- Pathology
Background:
- Arrhythmogenic cardiomyopathy (ACM) is an inherited heart muscle disease.
- It leads to sudden cardiac death, particularly in young patients and athletes.
- Pathological hallmarks include myocyte loss and fibrofatty replacement of the myocardium.
Purpose of the Study:
- To review the diagnosis and management of arrhythmogenic cardiomyopathy.
- To highlight the challenges in preventing sudden cardiac death in affected individuals.
- To discuss the role and limitations of implantable cardioverter defibrillators in ACM management.
Main Methods:
- Diagnostic criteria involve a scoring system integrating clinical, genetic, and imaging data.
- Genetic analysis focuses on desmosomal gene mutations.
- Treatment strategies primarily aim at sudden cardiac death prevention.
Main Results:
- ACM is characterized by cell-to-cell junction defects, often due to genetic desmosome abnormalities.
- Diagnosis is multifactorial, relying on a comprehensive scoring system.
- Implantable cardioverter defibrillators are the only proven therapy for sudden cardiac death prevention but carry risks.
Conclusions:
- Arrhythmogenic cardiomyopathy requires a multidisciplinary diagnostic approach.
- Effective management focuses on risk stratification and timely intervention for sudden cardiac death prevention.
- Careful patient selection for implantable cardioverter defibrillator implantation is crucial to balance benefits and risks.
Abstract:
Arrhythmogenic cardiomyopathy is an inherited heart muscle disorder, predisposing to sudden cardiac death, particularly in young patients and athletes. Pathological features include loss of myocytes and fibrofatty replacement of right ventricular myocardium; biventricular involvement is often observed. It is a cell-to-cell junction cardiomyopathy, typically caused by genetically determined abnormalities of cardiac desmosomes, which leads to detachment of myocytes and alteration of intracellular signal transduction. The diagnosis of arrhythmogenic cardiomyopathy does not rely on a single gold standard test but is achieved using a scoring system, which encompasses familial and genetic factors, ECG abnormalities, arrhythmias, and structural/functional ventricular alterations. The main goal of treatment is the prevention of sudden cardiac death. Implantable cardioverter defibrillator is the only proven lifesaving therapy; however, it is associated with significant morbidity because of device-related complications and inappropriate implantable cardioverter defibrillator interventions. Selection of patients who are the best candidates for implantable cardioverter defibrillator implantation is one of the most challenging issues in the clinical management.
Related Concept Videos
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy IV: Restrictive Cardiomyopathy
Mechanism of Cardiac Arrhythmias
Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Cardiomyopathy III: Hypertrophic Cardiomyopathy
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

